Evidence map›Paper›PMID 36080307›Full record

ArticleMolecules (Basel, Switzerland)2022

In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-

Zahid Rafiq Bhat, Manvendra Kumar, Nisha Sharma, Umesh Prasad Yadav, Tashvinder Singh, Gaurav Joshi, Brahmam Pujala, Mohd Raja, Joydeep Chatterjee, Kulbhushan Tikoo and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Design and Pictet-Spengler enabled synthesis of carboxamide-substituted imidazo[1,2-Journal of enzyme inhibition and medicinal chemistry · 2026
    Article
  2. Synthesis and Biological Activity of Azolo[Molecules (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Zahid Rafiq BhatDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Sahibzada Ajit Singh Nagar 160062, India.
Manvendra KumarLaboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda 151401, India.ORCID 0000-0002-6366-1661
Nisha SharmaDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Sahibzada Ajit Singh Nagar 160062, India.ORCID 0000-0002-7593-2676
Umesh Prasad YadavLaboratory of Molecular Medicine, Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda 151401, India.
Tashvinder SinghLaboratory of Molecular Medicine, Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda 151401, India.
Gaurav JoshiLaboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda 151401, India.ORCID 0000-0002-7812-2871
Brahmam PujalaIntegral BioSciences Pvt. Ltd., C-64, Hosiery Complex, Phase-II, Noida 201306, India.
Mohd RajaIntegral BioSciences Pvt. Ltd., C-64, Hosiery Complex, Phase-II, Noida 201306, India.
Joydeep ChatterjeeLaboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda 151401, India.
Kulbhushan TikooDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Sahibzada Ajit Singh Nagar 160062, India.
Sandeep SinghLaboratory of Molecular Medicine, Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda 151401, India.ORCID 0000-0001-8780-5124
Raj KumarLaboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda 151401, India.ORCID 0000-0001-5113-6627
Central University of Punjab · INNational Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad · IN

Funding

Council of Scientific and Industrial Research CSIR (02(0397)/21/EMR-II)Science and Engineering Research Board EMR/2017/002702
6 · The paper itself

Abstract

Tyrosine kinase inhibitors are validated therapeutic agents against EGFR-mutated non-small cell lung cancer (NSCLC). However, the associated critical side effects of these agents are inevitable, demanding more specific and efficient targeting agents. Recently, we have developed and reported a non-covalent imidazo[1,2-

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAnimalsCell Line, TumorCell ProliferationDrug Resistance, NeoplasmErbB ReceptorsHeterograftsHumansMiceMice, NudeMutationProtein Kinase InhibitorsQuinazolinesQuinoxalinesXenograft Model Antitumor AssaysErbB ReceptorsProtein Kinase InhibitorsQuinazolinesQuinoxalinesEGFR inhibitorimidazo[1,2-a]quinoxalineimmunoblottingin vivolung cancermicrosomal stabilityxenograft mice model

Identifiers

PMID36080307
PMCPMC9457798
OpenAlexW4293734838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.